Sixth Element Capital announces licence agreement with Nuvectis Inc on the HSF1 Programme

26th August, 2021

Read more


Sixth Element Capital welcomes Achilles Therapeutic’s announcement of its NASDAQ IPO

30th March, 2021

Read more


Sixth Element Capital welcomes NeoPhore Therapeutic’s announcement of its £15.2m Series B financing

9th March, 2021

Read more


Sixth Element Capital welcomes Achilles Therapeutic’s announcement of its £52.7m Series C financing

19th November, 2020

Read more


Sixth Element Capital welcomes Azeria Therapeutic’s announcement of its £32m Series B financing

21st November, 2019

Read more


Sixth Element Capital and Cancer Research UK Beatson Institute Announce Major Collaboration to Develop Novel RAS Inhibitors with Novartis

24th October, 2019

Read more


Sixth Element Capital welcomes Achilles Therapeutic’s announcement of its £100m Series B financing

3rd September, 2019

Read more


Sixth Element Capital announces licence agreement with Stemline Therapeutics on the RET Inhibitor Programme

11th March, 2019

Read more


Sixth Element Capital welcomes AdoRx Therapeutics Collaboration with Johnson and Johnson

28th February, 2019

Read more


Azeria Therapeutics announces Series A investment from Sixth Element Capital

4th September, 2018

Read more


AdoRx Therapeutics announces initial funding of $10 million for the discovery of new cancer therapeutics

21st June, 2018

Read more


Sixth Element Capital welcomes NeoPhore’s announcement of a £1m BioMedical Catalyst grant by Innovate UK

16th April, 2018

Read more


Sixth Element Capital welcomes Macrophage Pharma’s announcement of the appointment of Michael Moore as Chairman

11th April, 2018

Read more


Sixth Element Capital welcomes NeoPhore’s announcement of the appointment of Jeffrey Roix as Chief Executive Officer

11th April, 2018

Read more


Sixth Element Capital welcomes Sierra Oncology’s update on SRA737

1st March, 2018

Read more


Sixth Element Capital welcome the formation of NeoPhore’s Scientific Advisory Board

8th January, 2018

Read more


Sixth Element Capital welcomes Boston Pharmaceutical’s portfolio update including MPS1

5th January, 2018

Read more


NeoPhore scientific founders publish breakthrough immuno-oncology discoveries in Nature

29th November, 2017

Read more


PhoreMost and Sixth Element Capital announce creation and investment in NeoPhore, an immuno-oncology company

15th November, 2017

Read more


Sixth Element Capital welcomes Macrophage Pharma Limited’s announcement to Extend Series A Round to Include New Investor Merck Ventures

23rd August, 2017

Read more


CRT Pioneer Fund, Cancer Research UK and NCI collaborate to boost research against the ‘undruggable’ RAS

19th April, 2017

Read more


CRT Pioneer Fund and Cardiff University Announce the Initiation of the Phase II MONOCLE Study of Tefinostat

8th February, 2017

Read more


CRT Pioneer Fund and Cancer Research UK’s Manchester Institute nominate cancer drug candidate

20th January, 2017

Read more


Macrophage Pharma raises £9 million in Series A financing and acquires immune-oncology technology platform

9th January, 2017

Read more


CRT Pioneer Fund Announces Transfer of Sponsorship of SRA737 Clinical Trials

9th January, 2017

Read more


CRT Pioneer Fund announces investment in blood cancer drugs

8th December, 2016

Read more


Sixth Element Capital welcomes BACIT Ltd’s announcement to create £1 billion life science investment champion

7th November, 2016

Read more


Achilles Therapeutics launched with funds of £13.2 million to develop immunotherapies for cancer

5th October, 2016

Read more


ProNAi licenses oncology drug targeting DNA damage response checkpoint kinase 1 (chk1) from CRT Pioneer Fund, UK

27th September, 2016

Read more


Artios Pharma Company launch and fundraising of $33.2 miilion to focus on novel DNA damage response cancer therapies

21st September, 2016

Read more


CRT Pioneer Fund boosts investment in drugs that block cancer defences

5th May, 2016

Read more


CRT Pioneer Fund banks £20m investment from BACIT and expands agreement with Chroma Therapeutics to develop cancer immunotherapies

16th December, 2014

Read more


£50m CRT Pioneer Fund announces investment to develop lung cancer drugs at Cancer Research UK’s Manchester Institute

21st November, 2014

Read more


CRT Pioneer Fund collaborates with Chroma Therapeutics to develop cancer drugs targeting the immune system

31st October, 2013

Read more


CRT Pioneer Fund, BACIT and Sareum enter agreement to fund development of drugs to treat cancers including pancreatic, bowel and lung

24th September, 2013

Read more


The £50m CRT Pioneer Fund announces first investment to develop cancer drugs

23rd April, 2013

Read more


CRT and the EIF unveil innovative £50m cancer fund to bridge ‘development gap’ in UK

29th March, 2012

Read more